Can Lithium Cause Abnormal von Willebrand Activity?
No, lithium does not cause abnormal von Willebrand factor activity. The FDA-approved drug label for lithium does not list any effects on von Willebrand factor (VWF) or coagulation abnormalities among its extensive adverse reaction profile 1.
Evidence from Drug Labeling
The comprehensive FDA labeling for lithium carbonate details numerous adverse reactions across multiple organ systems, including:
- Hematologic effects: leukocytosis (increased white blood cells) and potential platelet increases
- Cardiovascular effects: arrhythmias, hypotension, sinus node dysfunction
- Renal, thyroid, neurologic, and metabolic complications
Notably absent from this extensive list is any mention of von Willebrand factor abnormalities, bleeding disorders, or coagulation defects 1.
Lithium's Known Hematologic Effects
Lithium's well-characterized hematologic effects are actually stimulatory rather than inhibitory:
- Increases neutrophils, eosinophils, and monocytes through enhanced production 2
- Tends to increase platelet counts, not decrease them 2, 3
- Stimulates colony-stimulating factor (CSF) production, promoting hematopoiesis 2
- Has been studied as a treatment for thrombocytopenia following chemotherapy, with statistically significant increases in platelet counts in patients with counts below 150,000/μL 3
This profile is opposite to what would be expected if lithium interfered with VWF function or caused bleeding tendencies.
Clinical Implications
When evaluating bleeding symptoms in a patient on lithium therapy:
- Do not attribute bleeding to lithium-induced VWF abnormalities—this is not a recognized effect
- Pursue standard diagnostic evaluation for von Willebrand disease as outlined in guidelines 4, including:
- VWF antigen (VWF:Ag)
- VWF ristocetin cofactor activity (VWF:RCo)
- Factor VIII coagulant activity (FVIII)
- Consider other causes of bleeding, including anatomic lesions, liver disease, or concurrent medications that affect hemostasis
- Be aware that lithium may actually increase platelet counts, which could theoretically improve rather than worsen hemostasis
Important Caveat
While lithium does not affect VWF, it does have significant effects on other organ systems that require monitoring, including renal function, thyroid function, and cardiac conduction 1. These should remain the focus of safety monitoring in lithium-treated patients, not coagulation parameters.